Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VSTM vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 56.9 HOLD), While VSTM Leads 3–2 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: VSTM 3 – 2 DMAC (1 Tie) Matrix Metrics: VSTM 5 – 3 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Verastem, Inc. (VSTM) on higher Unified Composite conviction (46.3/100 HOLD vs. 56.9/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while VSTM wins 3–2 across the 6-pillar growth and valuation breakdown. VSTM trades at $7.88 (N/M Forward P/E, -193.7% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VSTM currently prints a higher short-term Unified Composite Score (56.9/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -193.7% operating margin) and revenue trajectory (+0.0% vs. +113.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VSTM vs DMAC
VSTM NASDAQ
Verastem, Inc.
Pharmaceutical Preparations
$7.88
-3.67% 1D
Market Cap $1.1B
TTM Revenue $100M
Forward P/E N/M
Beta / 30D Vol 1.11β · 71% Vol
Unified Composite Score
56.9 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $9.30 · SMA50: $8.48
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (VSTM 3 – 2 DMAC)

Columns: Metric · VSTM · DMAC
1. Valuation Multiples VSTM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 10.2x N/M
2. Growth & Scale VSTM
Revenue Growth (YoY) +113.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $100M N/A
Market Cap $1.1B $503.1M
3. Profitability & Quality DMAC
Gross Margin 87.2% N/A
Operating Margin -193.7% 0.0%
Net Profit Margin -178.4% 0.0%
Return on Equity (ROE) -471.2% -114.6%
4. Balance Sheet & Cash Flow VSTM
Cash Generation (TTM) -$168M -$32M
Cash Flow Margin N/A N/A
Net Cash / Leverage $44M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 96.8% (10th %ile) 106.3% (14th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VSTM (5) vs DMAC (3)
Institutional Metric VSTM DMAC Criterion Row Edge
Market Capitalization
Scale
$1.1B $503.1M Larger Scale VSTM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+113.6% +0.0% Higher Growth VSTM
Operating Margin (TTM)
Profitability
-193.7% 0.0% Higher Margin DMAC
Net Profit Margin
Profitability
-178.4% 0.0% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-471.2% -114.6% Higher ROE DMAC
52-Week Range Position
Momentum
60% ($3–$11) 55% ($5–$11) Stronger Trend VSTM
Beta / 30D Volatility
Risk Regime
1.11β · 71% Vol 1.74β · 98% Vol Lower Realized Risk VSTM
Unified Institutional Score
Composite Signal
56.9 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite VSTM
Trailing 12M Revenue (USD)
Operating Scale
$100M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 10.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$168M ($44M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +20.06 pp
VSTM: -8.9% · DMAC: +11.16%
3M Horizon DMAC +21.25 pp
VSTM: +6.06% · DMAC: +27.31%
6M Horizon VSTM +36.83 pp
VSTM: +84.98% · DMAC: +48.15%
1Y Horizon DMAC +58.1 pp
VSTM: -2.84% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VSTM Revenue DMAC Revenue VSTM Op. Margin DMAC Op. Margin Margin Leader
FY2018 $30M $0M -354.8% -1352.2% VSTM
FY2019 $20M N/A -758.1% N/A VSTM
FY2020 $90M N/A -55.8% N/A VSTM
FY2021 $0M N/A -2991.2% N/A VSTM
FY2022 $0M N/A -2809.6% N/A VSTM
FY2024 $10M N/A -1149.6% N/A VSTM
FY2025 $30M N/A -550.3% N/A VSTM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VSTM CONSOLIDATION
50d in phase · OBV NEUTRAL
Current IV 96.8%
IV Percentile 10th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VSTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VSTM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and -193.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VSTM vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Verastem, Inc. (VSTM) on higher Unified Composite conviction (46.3/100 HOLD vs. 56.9/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while VSTM wins 3–2 across the 6-pillar growth and valuation breakdown. VSTM trades at $7.88 (N/M Forward P/E, -193.7% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VSTM currently prints a higher short-term Unified Composite Score (56.9/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -193.7% operating margin) and revenue trajectory (+0.0% vs. +113.6% YoY).

VSTM leads the Growth & Scale pillar: VSTM posts +113.6% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (87.2% gross margin, -193.7% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2018 to FY2025), VSTM cumulative revenue shifted +0.0% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, VSTM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

VSTM screens cheaper on headline valuation multiples. VSTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 10.2x EV/Revenue (unreported FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VSTM (-471.2% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VSTM carries 96.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.11β · 71% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.